日本制药公司卫材 (Eisai) 计划于 9 月份在中国推出阿尔茨海默病药物 Leqembi，用于治疗 1,500 名患者，由于新兴的诊断方法，预计销售额将在 2025 年实现增长。 Japanese pharma Eisai plans to launch Alzheimer's drug Leqembi in China for 1,500 patients by Sept, with sales expected to grow in 2025 due to emerging diagnostic methods.
日本卫材公司计划今年晚些时候向中国的 1,500 名患者推出其突破性阿尔茨海默病药物 Leqembi，由于诊断方法的改变，预计到 2025 年将出现显着增长。 Japan's Eisai is planning to launch its groundbreaking Alzheimer's drug, Leqembi, to 1,500 patients in China later this year, with significant growth expected in 2025 due to changes in diagnosis methods. 该公司的目标是通过更便捷的血液检测，为中国约 1700 万早期阿尔茨海默病患者提供更多服务。 The company aims to reach a larger share of China's estimated 17 million people with early-stage Alzheimer's disease through more convenient blood tests. 由于人口老龄化以及 Leqembi 的大幅增长潜力，卫材将中国视为一个重要市场。 Eisai sees China as a crucial market due to its aging population and the potential for substantial growth for Leqembi.